Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection - PubMed (original) (raw)

Review

. 2020 Apr 27;192(17):E450-E453.

doi: 10.1503/cmaj.200528. Epub 2020 Apr 8.

Affiliations

• PMID: 32269021
• PMCID: PMC7207200
• DOI: 10.1503/cmaj.200528

Review

Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection

David N Juurlink. CMAJ. 2020.

Erratum in

• Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.
  [No authors listed] [No authors listed] CMAJ. 2020 May 25;192(21):E590. doi: 10.1503/cmaj.200978. CMAJ. 2020. PMID: 32575065 Free PMC article. No abstract available.

No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Comment in

• Additional safety consideration for azithromycin in the management of SARS-CoV-2 infection.
  Seftel MD. Seftel MD. CMAJ. 2020 May 4;192(18):E483. doi: 10.1503/cmaj.75427. CMAJ. 2020. PMID: 32366470 Free PMC article. No abstract available.

Similar articles

• Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19.
  Gevers S, Kwa MSG, Wijnans E, van Nieuwkoop C. Gevers S, et al. Clin Microbiol Infect. 2020 Sep;26(9):1276-1277. doi: 10.1016/j.cmi.2020.05.006. Epub 2020 May 16. Clin Microbiol Infect. 2020. PMID: 32422406 Free PMC article. No abstract available.
• Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.
  Saleh M, Gabriels J, Chang D, Soo Kim B, Mansoor A, Mahmood E, Makker P, Ismail H, Goldner B, Willner J, Beldner S, Mitra R, John R, Chinitz J, Skipitaris N, Mountantonakis S, Epstein LM. Saleh M, et al. Circ Arrhythm Electrophysiol. 2020 Jun;13(6):e008662. doi: 10.1161/CIRCEP.120.008662. Epub 2020 Apr 29. Circ Arrhythm Electrophysiol. 2020. PMID: 32347743 Free PMC article.
• Potential pro-arrhythmic effects of pharmacotherapy against SARS-CoV-2.
  Medeiros-Domingo A, Carrasco OF, Berni-Betancourt A. Medeiros-Domingo A, et al. Arch Cardiol Mex. 2020;90(Supl):36-40. doi: 10.24875/ACM.M20000061. Arch Cardiol Mex. 2020. PMID: 32523150 English.
• Of chloroquine and COVID-19.
  Touret F, de Lamballerie X. Touret F, et al. Antiviral Res. 2020 May;177:104762. doi: 10.1016/j.antiviral.2020.104762. Epub 2020 Mar 5. Antiviral Res. 2020. PMID: 32147496 Free PMC article. Review.
• Will Hydroxychloroquine Still Be a Game-Changer for COVID-19 by Combining Azithromycin?
  Li C, Cheng G. Li C, et al. Front Immunol. 2020 Aug 7;11:1969. doi: 10.3389/fimmu.2020.01969. eCollection 2020. Front Immunol. 2020. PMID: 32849658 Free PMC article. Review.

Cited by

• Off-label prescription: developing a guideline and validating an instrument to measure physicians' and clinical pharmacists' knowledge and attitudes toward off-label medication use.
  Salari P, Larijani B, Zahedi F, Noroozi M. Salari P, et al. J Diabetes Metab Disord. 2023 Sep 2;22(2):1599-1608. doi: 10.1007/s40200-023-01288-0. eCollection 2023 Dec. J Diabetes Metab Disord. 2023. PMID: 37975085 Free PMC article.
• An Overview of Repurposed Drugs for Potential COVID-19 Treatment.
  Govender K, Chuturgoon A. Govender K, et al. Antibiotics (Basel). 2022 Nov 22;11(12):1678. doi: 10.3390/antibiotics11121678. Antibiotics (Basel). 2022. PMID: 36551336 Free PMC article. Review.
• Toxicology evaluation of overdose hydroxychloroquine on zebrafish (Danio rerio) embryos.
  Luo M, Xie D, Lin Z, Sun H, Liu Y. Luo M, et al. Sci Rep. 2022 Oct 29;12(1):18259. doi: 10.1038/s41598-022-23187-9. Sci Rep. 2022. PMID: 36309536 Free PMC article.
• Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure-Activity Relationship Insights and Evolution Perspectives.
  La Monica G, Bono A, Lauria A, Martorana A. La Monica G, et al. J Med Chem. 2022 Oct 13;65(19):12500-12534. doi: 10.1021/acs.jmedchem.2c01005. Epub 2022 Sep 28. J Med Chem. 2022. PMID: 36169610 Free PMC article. Review.
• Antiparasitic Drugs against SARS-CoV-2: A Comprehensive Literature Survey.
  Calvo-Alvarez E, Dolci M, Perego F, Signorini L, Parapini S, D'Alessandro S, Denti L, Basilico N, Taramelli D, Ferrante P, Delbue S. Calvo-Alvarez E, et al. Microorganisms. 2022 Jun 24;10(7):1284. doi: 10.3390/microorganisms10071284. Microorganisms. 2022. PMID: 35889004 Free PMC article. Review.

References

1. 1. Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005;2:69. - PMC - PubMed
2. 1. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30: 269–71. - PMC - PubMed
3. 1. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020. Mar. 9 [Epub ahead of print]. pii ciaa237. 10.1093/cid/ciaa237. - DOI - PMC - PubMed
4. 1. Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020;14:72–3. - PubMed
5. 1. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020. Mar. 20:105949 [Epub ahead of print]. 10.1016/j.ijantimicag.2020.105949. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Europe PubMed Central
  • HighWire
  • Ovid Technologies, Inc.
  • PubMed Central

• Miscellaneous

  • NCI CPTAC Assay Portal